Compare Capri Holdings Ltd (CPRI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Ginkgo Bioworks Holdings Inc — how do they compare? Capri Holdings Ltd trades at $16.4 (market cap $1.91B), while Ginkgo Bioworks Holdings Inc trades at $9.01 (market cap $590.53M). The key difference: Capri Holdings Ltd is far larger — about 3.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | DNA | |
|---|---|---|
Market Cap | $1.91B | $590.53M |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $16.14 |
52-Week Low | $16.68 | $5.48 |
Enterprise Value | $3.20B | $627.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $17.46, down 3.22% on the day, with a bearish technical signal from moving averages and oscillators neutral. The company reported a net loss of $1.18 billion in 2025 despite a gross profit margin of 62.26%. Recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo, with management projecting fiscal 2027 growth. Analyst consensus is a buy rating with a $23.33 price target, implying significant upside from current levels.
The investment case hinges on successful execution of the two-brand strategy and return to profitability. Key risks include sustained luxury demand weakness and high debt levels, while potential rewards include valuation upside if earnings guidance is met. The stock presents a high-risk, high-reward opportunity contingent on operational improvements.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
